Target Health Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: New York NY United States (1993)

Organization Overview

First Clinical Trial
2011
NCT01220206
First Marketed Drug
2012
taliglucerase alfa (elelyso)
First NDA Approval
2012
taliglucerase alfa (elelyso)
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Target Health Inc.

Active Ingredients

Marketed Drugs (1)

taliglucerase alfa (elelyso) (2012 NDA)

Drugs in Phase 3 Trials (4)

cycloserine (seromycin) (3 trials)

ketamine (ketalar) (1 trial)

lurasidone (latuda) (4 trials)

nrx-101 (1 trial)

Drugs in Phase 2 Trials (3)

abametapir (1 trial)

aviptadil (1 trial)

pomx (1 trial)

Drugs in Other Trials (1)

sorbitol (1 trial)

Indications

Approved Indications


 

Gaucher Disease

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Bipolar Disorder (Phase 3)

Coronavirus Infections (Phase 2)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Erectile Dysfunction (Phase 2)

Lice Infestations (Phase 2)

Lung Injury (Phase 2)

Mite Infestations (Phase 2)

Parasitic Diseases (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Suicidal Ideation (Phase 3)

Suicide (Phase 3)

Suicide, Attempted (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 8